<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867800</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ2350</org_study_id>
    <nct_id>NCT02867800</nct_id>
  </id_info>
  <brief_title>Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease</brief_title>
  <official_title>Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monica Bhatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when&#xD;
      added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin&#xD;
      inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine,&#xD;
      thiotepa, melphalan, and alemtuzumab for conditioning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcomes of hematopoietic stem cell transplantation (HSCT) for children and adolescents with&#xD;
      sickle cell disease (SCD) have improved. Graft versus host disease (GVHD), however, remains a&#xD;
      barrier to success. GVHD accounts for most of the transplant related mortality and much of&#xD;
      the morbidity in this setting-in part through the injury it directly causes and in part&#xD;
      through the deleterious effects of steroids and the other immunosuppressive agents used to&#xD;
      prevent and treat it. The results of pre-clinical studies and a phase I clinical study in&#xD;
      patients with hematologic malignancies suggest that the costimulation blocking agent CTLA4-Ig&#xD;
      may hold promise an agent for GVHD prophylaxis. In the present trial, the investigators are&#xD;
      assessing the tolerability of adding abatacept to standard GVHD prophylaxis-a calcineurin&#xD;
      inhibitor and methotrexate-in pediatric SCD patients receiving early alemtuzumab (completed&#xD;
      by day -18) followed by fludarabine, thiotepa, and melphalan for conditioning. This trial&#xD;
      will provide the foundation for subsequent trials designed to test the long-term hypothesis&#xD;
      that abatacept is a safe, steroid-sparing effective adjunct to standard GVHD prophylaxis in&#xD;
      this setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who tolerate abatacept</measure>
    <time_frame>Within 100 days of receiving the last prescribed dose of abatacept</time_frame>
    <description>Patients will be deemed to be evaluable for tolerability if they received all prescribed doses of abatacept.&#xD;
Abatacept will deemed to be tolerated, if no more than one dose is withheld per protocol stipulations, no death from an infection that occurs within 30 days of or develops post-transplant lymphoproliferative disease (PTLD) within 100 days of receiving the last prescribed dose of abatacept.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bearman Scale Score of Regimen-Related Toxicity (RRT)</measure>
    <time_frame>Day 42 post-transplant</time_frame>
    <description>RRT will be assessed according to Bearman Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infections</measure>
    <time_frame>Up to 180 days post transplant</time_frame>
    <description>Infections will include viremia, posttransplant lymphoproliferative disease and immune reconstitution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive&#xD;
premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)&#xD;
immunosuppression (Alemtuzumab, or Thymoglobulin)&#xD;
conditioning regimen (Fludarabine, Thiotepa, and Melphalan)&#xD;
GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>(Standard of Care) Premedication&#xD;
Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>(Standard of Care) Premedication&#xD;
Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>(Standard of Care) Premedication&#xD;
Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <description>(Standard of Care) Premedication&#xD;
Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Demerol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>(Standard of Care) Immunosuppression&#xD;
Alemtuzumab:&#xD;
A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>(Standard of Care) Immunosuppression&#xD;
Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Genzyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>(Standard Conditioning Regimen)&#xD;
Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>(Standard Conditioning Regimen)&#xD;
Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>(Standard Conditioning Regimen)&#xD;
Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Thioplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>(Standard GVHD Prophylaxis) Calcineurin inhibitor&#xD;
Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>(Standard GVHD Prophylaxis) Calcineurin inhibitor&#xD;
Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>(Standard GVHD Prophylaxis)&#xD;
Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>(Investigational)&#xD;
Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>CTLA4-Ig</other_name>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Marrow infusion</intervention_name>
    <description>(Standard)&#xD;
A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>stem cell transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>(Standard GVHD Prophylaxis)&#xD;
Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>(Standard GVHD Prophylaxis)&#xD;
Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used.</description>
    <arm_group_label>Standard GVHD Prophylaxis + Abatacept</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with hemoglobin (Hgb) SS or SB0 thalassemia between the ages of 3 and 20.99&#xD;
             years who are at least 10 kg getting an human leukocyte antigen (HLA) matched bone&#xD;
             marrow transplant, will be eligible if they are at increased risk for graft versus&#xD;
             host disease (GVHD) and have severe SCD.&#xD;
&#xD;
             (a) Patients falling into one of the following three groups will be considered to be&#xD;
             at increased risk for GVHD:&#xD;
&#xD;
             (i) Are between 10 and 20.99 years and receiving their transplant from an HLA matched&#xD;
             related donor.&#xD;
&#xD;
             (ii) Are between 3 and 9.99 years and receiving their transplant from an HLA matched&#xD;
             related donor who is at least 10 years.&#xD;
&#xD;
             (iii) Are between 3 and 20.99 years and receiving their transplant from an HLA matched&#xD;
             unrelated donor. Donors must be matched at the A, B, C and DRB1 loci at the allele&#xD;
             level.&#xD;
&#xD;
             (b) Patients who meet one of the following criteria will qualify as having severe SCD:&#xD;
&#xD;
             (i) Previous clinical stroke, as evidenced by a neurological deficit lasting longer&#xD;
             than 24 hours, which is accompanied by radiographic evidence of ischemic brain injury&#xD;
             and cerebral vasculopathy.&#xD;
&#xD;
             (ii) Asymptomatic cerebrovascular disease, as evidenced by one the following:&#xD;
&#xD;
               -  Progressive silent cerebral infarction, as evidenced by serial MRI scans that&#xD;
                  demonstrate the development of a succession of lesions (at least two temporally&#xD;
                  discreet lesions, each measuring at least 3 mm in greatest dimension on the most&#xD;
                  recent scan) or the enlargement of a single lesion, initially measuring at least&#xD;
                  3 mm). Lesions must be visible on T2-weighted MRI sequences.&#xD;
&#xD;
               -  Cerebral arteriopathy, as evidenced by abnormal transcranial doppler (TCD)&#xD;
                  testing (confirmed elevated velocities in any single vessel of time-averaged&#xD;
                  maximum mean velocities (TAMMV) &gt; 200 cm/sec for non-imaging TCD) or by&#xD;
                  significant vasculopathy on magnetic resonance angiogram (MRA) (greater than 50%&#xD;
                  stenosis of &gt; 2 arterial segments or complete occlusion of any single arterial&#xD;
                  segment).&#xD;
&#xD;
             (iii) Frequent ( ≥ 3 per year for preceding 2 years) painful vaso-occlusive episodes&#xD;
             (defined as episode lasting ≥ 4 hours and requiring hospitalization or outpatient&#xD;
             treatment with parenteral opioids). If patient is on hydroxurea and its use has been&#xD;
             associated with a decrease in the frequency of episodes, the frequency should be&#xD;
             gauged from the 2 years prior to the start of this drug.&#xD;
&#xD;
             (iv) Recurrent ( ≥ 3 in lifetime) acute chest syndrome events which have necessitated&#xD;
             erythrocyte transfusion therapy.&#xD;
&#xD;
             (v) Any combination of ≥ 3 acute chest syndrome episodes and vaso-occlusive pain&#xD;
             episodes (defined as above) yearly for 3 years. If patient is on hydroxurea and its&#xD;
             use has been associated with a decrease in the frequency of episodes, the frequency&#xD;
             should be gauged from the 3 years prior to the start of this drug.&#xD;
&#xD;
          2. All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent. Assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines.&#xD;
&#xD;
          3. Must have been evaluated and adequately counseled regarding treatment options for&#xD;
             severe SCD by a pediatric hematologist.&#xD;
&#xD;
          4. Because of the elective and non-urgent nature of hematopoietic stem cell&#xD;
             transplantation (HSCT) for SCD, it is important that all patients and families be&#xD;
             counseled regarding fertility preservation measures available to them. All patients&#xD;
             and/or their parents or legal guardians must indicate on the consent and assent forms&#xD;
             that they have received this counseling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bridging (portal to portal) fibrosis or cirrhosis of the liver.&#xD;
&#xD;
          2. Parenchymal lung disease stemming from SCD or other process defined as a diffusing&#xD;
             capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) or forced&#xD;
             vital capacity of less than 45% of predicted. Children unable to perform pulmonary&#xD;
             function testing will be excluded if they require daytime oxygen supplementation.&#xD;
&#xD;
          3. Renal dysfunction with an estimated glomerular filtration rate (GFR) &lt; 50% of&#xD;
             predicted normal for age.&#xD;
&#xD;
          4. Cardiac dysfunction with shortening fraction &lt; 25%.&#xD;
&#xD;
          5. Neurologic impairment other than hemiplegia, defined as full-scale IQ ≤70,&#xD;
             quadriplegia or paraplegia, inability to ambulate, or any impairment resulting in&#xD;
             decline of Lansky performance score to &lt; 70%.&#xD;
&#xD;
          6. Clinical stroke within 6 months of anticipated transplant.&#xD;
&#xD;
          7. Karnofsky or Lansky functional performance score &lt; 70%.&#xD;
&#xD;
          8. Patient is human immunodeficiency virus (HIV) infected.&#xD;
&#xD;
          9. Donor is HIV infected.&#xD;
&#xD;
         10. Donor has Hgb SS, SC or SB0 thalassemia.&#xD;
&#xD;
         11. Patient with unspecified chronic toxicity serious enough to detrimentally affect the&#xD;
             patient's capacity to tolerate bone marrow transplantation.&#xD;
&#xD;
         12. Patient or patient's guardian(s) unable to understand the nature and risks inherent in&#xD;
             the bone marrow transplant (BMT) process.&#xD;
&#xD;
         13. History of lack of compliance with medical care that would jeopardize transplant&#xD;
             course.&#xD;
&#xD;
         14. Donor who for psychological, physiologic, or medical reasons is unable to tolerate a&#xD;
             bone marrow harvest or receive general anesthesia.&#xD;
&#xD;
         15. Active viral, bacterial, fungal or protozoal infection.&#xD;
&#xD;
         16. Donor is pregnant.&#xD;
&#xD;
         17. Patient is pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Bhatia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Cancer Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Monica Bhatia</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>Abatacept</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

